Kevin Watson - Rosetta Genomics Director, Reimbursement-Managed Care

Director

Mr. Kevin Watson served as the Director, ReimbursementManaged Care of the Company. Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization. Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement. Prior to this, Mr. Watson was the President of GlobalPayer, a payer relations and reimbursement consulting and outsourcing company serving providers and manufacturers in the medical device and diagnostic industry. Mr. Watson was the Regional MarketingPayer Relations Director at Becton Dickinson Diagnostics TriPath Imaging for 6 years, where he was responsible for the development, execution and management of reimbursement outcomes with large payer organizations, Medicare and Medicaid. Previous to that, Mr. Watson held positions as Executive Director, Business Development at LabCorporation, and Network Product Development Leader, Executive Director with Quest Diagnostics, Inc. Mr. Watson started his career in payer management at Aetna Health Plans, where he spent four years as Administrator, National Vendor Contracting. since 2014.
Tenure 10 years
Phone972 73 222 0700
Webhttp://www.rosettagx.com

Rosetta Genomics Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Robert KohlheppParker Hannifin
72
Thomas WilliamsChart Industries
59
Kenichi NagaiNH Foods
N/A
Fumio MaedaNH Foods
58
Shuji OhkosoNH Foods
N/A
Toshiyuki HaginoNH Foods
N/A
Juan SabogalCementos Pacasmayo SAA
46
Margaret WhelanTopbuild Corp
45
Lee WeldonNatural Alternatives Internatio
78
Kevin LoboParker Hannifin
55
Hiroyuki YanoNH Foods
N/A
Candy ObournParker Hannifin
69
Hugo CastilloCementos Pacasmayo SAA
62
Richard OkumotoLifevantage
63
Kenya MaruyamaNH Foods
N/A
Terrence KeatingChart Industries
66
Alan LaneNatural Alternatives Internatio
55
Hiroyuki TsukudaNH Foods
N/A
Dionisio PaolettiCementos Pacasmayo SAA
51
Shunichi OgataNH Foods
N/A
Jim MayChart Industries
N/A
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people. Rosetta Genomics (ROSG) is traded on NASDAQ Exchange in USA and employs 86 people.

Management Performance

Rosetta Genomics Leadership Team

Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director
Kenneth Berlin, CEO and Pres
Anne Fields, IR Contact Officer
Joshua Rosensweig, Director
Dganit Bar, Chief Scientific Officer
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee
Douglas Sites, Executive Vice President - Sales and Marketing
Tal YaronEldar, Independent Director
Eti Meiri, Vice President - Research
Robert Wassman, Chief Medical Officer
Oded Biran, General Counsel
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director, Reimbursement-Managed Care
Ron Kalfus, CFO
Gerald Dogon, External Independent Director
Tali YaronEldar, External Independent Director

Rosetta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in Rosetta Stock

If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio